Skip to main content

Table 5 Prognostic factors of PFS or OS

From: Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer

Factors

PFS

OS

Sex (male/female)

0.426

0.302

Age (61/<61)

0.706

0.084

CRP (1.5/<1.5)

0.654

0.832

Hemoglobin (12/<12)

0.351

0.435

Lymphocyte (%) (27/<27)

0.145

0.132

Lymphocyte (number) (1500/<1500)

0.488

0.900

CDCA1 CTL spots (2+/<2+)

0.004

0.870

CHD3 CTL spots (2+/<2+)

0.235

0.611

KIF20A CTL spots (2+/<2+)

0.486

0.840

CXCR3 + CCR4- T cells (8%/<8%)

0.046

0.966

CXCR3 + CCR4- T cells (up/down)

0.007

0.604

Injection site reaction (Grade2/

0.145

0.003

Continuous vaccination after PD (Yes/No)

-

0.007